Sol-Gel Technologies’ work to expand the treatment options for patients with the skin condition rosacea has paid off, with the FDA approving a product based on its microencapsulation technology.
Sol-Gel Technologies (NASDAQ:SLGL) said it is acquiring topically-applied drug patidegib from PellePharm, and separately announced $22.8M registered direct and private placement offerings. Sol-Gel ...
NESS ZIONA, Israel, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. , a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical ...
Sol-Gel Technologies secures $16 million for clinical trials, advancing SGT-610 for Gorlin syndrome and extending cash runway to 2027. Sol-Gel Technologies, Ltd. has announced a product purchase ...
LONDON--(BUSINESS WIRE)--The sol-gel coatings market is expected to grow by USD 2.63 billion during 2020-2024, according to Technavio. The report offers a detailed analysis of the impact of COVID-19 ...
Just because a business does not make any money, does not mean that the stock will go down. For example, Sol-Gel Technologies (NASDAQ:SLGL) shareholders have done very well over the last year, with ...
Sol-Gel Technologies (SLGL) has released an update. Sol-Gel Technologies announced a significant improvement in its financial performance for Q3 2024, with a reduction in net losses and an increase in ...
In the case of Sol-Gel Technologies Ltd. (NASDAQ:SLGL), the share price is up an incredible 940% in the last year alone. It's also good to see the share price up 106% over the last quarter. It is also ...
NESS ZIONA, Israel & LAUSANNE, Switzerland--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results